Far from being a passive regulator, the US FDA is sometimes the one pushing the efficacy bar higher in a therapeutic category.
Such was the case in the regulatory review of Gilead Sciences Inc.'s hepatitis C combination therapy Epclusa (sofosbuvir/velpatasvir). Despite...








